People can experience bouts of urticaria over the course of their lives, but usually they only last for a matter of days. When the symptoms last six weeks or more, it can be classified as chronic idiopathic urticaria.
Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.
A review of studies concludes that switching psoriatic arthritis patients who have stopped responding to one tumor necrosis factor inhibitor (TNFi) to another will likely reduce their symptoms, but the effectiveness of each new medication will likely be less than each former medication.
A recent review of current research on atopic dermatitis (AD) treatments found that a clearer understanding of the pathogenesis of the phenotypes involved in the disease will lead to advances in new therapies.
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.
Dermatitis researchers use far too many instruments in measuring symptoms of skin ailments, a study found. Symptoms of atopic ezcema/dermatitis (AD) were found in a systematic review of randomized controlled trials (RCTs) to be most often characterized from composite measures rather than stand-alone symptom severity rating instruments, and thirty different instruments were found to have been used across 378 trials.
Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.